BiotechTube

Andexanet alfa + 4F-PCC

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anticoagulant-related Major Bleed

Conditions

Anticoagulant-related Major Bleed

Trial Timeline

Sep 15, 2022 → Dec 20, 2022

NCT ID
NCT05548777

About Andexanet alfa + 4F-PCC

Andexanet alfa + 4F-PCC is a pre-clinical stage product being developed by AstraZeneca for Anticoagulant-related Major Bleed. The current trial status is completed. This product is registered under clinical trial identifier NCT05548777. Target conditions include Anticoagulant-related Major Bleed.

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05548777Pre-clinicalCompleted